Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial
机构：[1]Sun Yat-sen University Cancer Center, Guangzhou, China[2]Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China[3]Thoracic Medicine Department 1, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China[4]Yunnan Cancer Hospital, Kunming, China[5]Sun Yat-sen University Cancer Center, Guang Zhou, China[6]Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, China[7]The Second Hospital of Anhui Medical University, Hefei, China[8]Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China[9]Tianjin Cancer Hospital, Tianjin, China[10]Renmin Hospital of Wuhan University, Wuhan, China[11]Department of Oncology, Mianyang Central Hospital, Mianyang, China[12]Respiratory Medicine Department, Shandong Cancer Hospital and Institute, Jinan, China[13]The First Affiliated Hospital of Bengbu Medical College, Bengbu, China[14]The First Affiliated Hospital of Nanchang University, Nanchang, China[15]The Fourth Hospital of Hebei Medical University, Shijiazhuang, China河北医科大学第四医院[16]Weifang No.2 People’s Hospital, Weifang, China[17]Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China浙江省肿瘤医院[18]Akeso Biopharma, Inc., Zhongshan, China
第一作者机构：[1]Sun Yat-sen University Cancer Center, Guangzhou, China
推荐引用方式(GB/T 7714)：
Zhang Li,Fang Wenfeng,Zhao Yuanyuan,et al.Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial[J].JOURNAL OF CLINICAL ONCOLOGY.2024,42(16):
APA：
Zhang, Li,Fang, Wenfeng,Zhao, Yuanyuan,Luo, Yongzhong,Yang, Runxiang...&Xia, Yu.(2024).Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial.JOURNAL OF CLINICAL ONCOLOGY,42,(16)
MLA：
Zhang, Li,et al."Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial".JOURNAL OF CLINICAL ONCOLOGY 42..16(2024)
医学